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Abstract
Background: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of α-galactosidase
A and the resulting accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and its derivatives,
including globotriaosylsphingosine (Lyso-Gb3). Increased cellular and plasma levels of Gb3 and Lyso-Gb3 affect
multiple organs, with specific clinical consequences for the kidneys, heart and brain.
There is growing evidence that alterations in glycosphingolipids may have an oncogenic role and this prompted a
review of cases of cancer and benign lesions in a large single centre cohort of Fabry patients. We also explored
whether there is a difference in the risk of cancer in Fabry patients compared to the general population.
Results: Our results suggest that Fabry patients may have a marginally reduced rate of all cancer (incidence rate
ratio 0.61, 95% confidence interval 0.37 to 0.99) but possibly increased rates of melanoma, urological malignancies
and meningiomas.
Conclusion: Greater knowledge and awareness of cancer in patients with Fabry disease may help identify at-risk
individuals and elucidate cancer mechanisms in this rare inherited disease, which may potentially be relevant to the
wider cancer population.
Keywords: Fabry disease, Lysosomal storage disorders, Haematology, Genetics, Cancer: Urological, Cancer:
Dermatological, Cancer: CNS
Background
Fabry disease, one of the most prevalent lysosomal storage
disorders (LSD), is caused by mutations in the GLA gene
which leads to partial or complete deficiency of the
lysosomal enzyme α-galactosidase A (AGAL A, OMIM
*300644). Over 800 different mutations have been recorded
in Fabry patients, including a variety of missense or non-
sense point mutations, splicing mutations, deletions and in-
sertions [1]. Although the inheritance of Fabry disease is X-
linked, up to 70% of heterozygote females are symptomatic,
with some experiencing severe disease manifestations, simi-
lar to males [1, 2]. The mechanism behind this may in part
be skewed X-inactivation but this is an area of debate [3, 4].
Reduced or absent activity of AGAL A results in accu-
mulation of globotriaosylceramide (Gb3) and its deriva-
tives, including globotriaosylsphingosine (lyso-Gb3), in
plasma and cells throughout the body [5]. Clinical features
include neuropathic pain, characteristic angiokeratoma,
gastrointestinal symptoms and fatigue, and ultimately
renal failure, cardiomyopathy and stroke [6]. Two broad
clinical phenotypes are recognised (although there is likely
to be a continuum); an early onset classical form exhibit-
ing pain, angiokeratoma and sweating abnormalities pre-
ceding overt kidney and heart disease, and a later onset
form with predominant manifestation in a single organ,
usually the heart [6].
Therapy is essentially replacement of the deficient en-
zyme by intravenous enzyme replacement therapy (agalsi-
dase alfa (Shire), agalsidase beta (Genzyme Sanofi)) or oral
pharmacological chaperone therapy (Migalastat (Amicus
therapeutics)). Gene therapy is also in development [7].
The pathophysiological link between accumulation of
Gb3/Lyso-Gb3 and organ pathology, such as fibrosis, is
not well understood. Substrate accumulation may lead to
ischemia and cell death or initiate other downstream pro-
cesses including inflammation, apoptosis or formation of
reactive oxygen species [8]. Glycosphingolipids (GSL) have
themselves been implicated in both oncogenesis and po-
tential cancer therapies [9]. They are an integral part of
the cell membrane and exhibit heterogeneous glycosyla-
tion and ceramide structures, thereby functioning as anti-
gens, mediators of cell adhesion and modulators of signal
transduction [10]. Specific GSLs may be highly expressed
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in tumour cells and act as adhesion molecules in tumour
cell metastasis and modulators of tumor growth [10].
Elevated expression of Gb3 has been identified in mul-
tiple cancer types, including breast, colon, pancreatic,
gastric, ovarian, testicular and lymphoma [11–17]. Fur-
thermore, Gb3 expression correlates with the metastatic
potential of human colon cancer and Gb3 enriched
colon cancer cells have invasive characteristics, for
which Gb3 expression is necessary and sufficient [18].
Other glycosphingolipids relevant to cancer and Fabry
disease include sphingosine-1-phosphate (S1P) and
Lyso-Gb3, both of which promote cell proliferation and
have been found at higher levels in the plasma of male
patients compared to the plasma of controls [5, 19, 20].
The incidence of cancer in patients with Gaucher dis-
ease, an LSD in which there is accumulation of the GSL
glucocerebroside due to deficiency of glucocerebrosi-
dase, has been reported [21–24]. The evidence is most
persuasive of an increased risk of haematological cancer,
especially multiple myeloma [21–25]. However, only a
handful of case reports have been published describing
cancer in individuals with Fabry disease and there has
been no systematic study of the relative incidence of
cancer in the context of Fabry disease compared to the
general population [26–30].
In this study, we use retrospective data from hospital
notes and patient questionnaires to review the incidence
of cases of cancer and benign lesions within a large sin-
gle centre patient cohort.
Methods
Patients and data collection
Adult patients (age > 18 years) who attended the Royal
Free Hospital Lysosomal Storage Disorder Unit between
2012 and 2016 were eligible for inclusion in the study.
Notes of patients who had consented to the retros-
pective database were reviewed. Additionally, a question-
naire regarding the incidence of cancer in patients and
families was administered. The questionnaire had
received ethical approval and all patients returning the
questionnaire consented to do so. Two hundred sixty
one patients were included; 11 patients were excluded
from the analysis because data were insufficient, the
patient was lost to follow-up before 2012 or no ques-
tionnaire had been returned.
Data collection included: gender, date of birth, treat-
ment status, occurrence of cancer since birth (with year
of occurrence) and occurrence of benign lesion since
birth (with year of occurrence). Benign lesions included
precancerous lesions (a histological lesion that, with time,
has an increased risk of developing into cancer, for example
cervical intraepithelial neoplasm), proliferative lesions (a be-
nign tumour that does not have metastatic potential, such
as a meningioma, but can cause complications e.g. due to
its space occupying effect) and other lesions (such as a
cholesteatoma, which is an abnormal collection of keratin).
Analysis of results and statistical methods
In order to compare cancer incidence in the general
population and Fabry population, cancer incidence rates
for both cohorts were calculated. The cancer incidence
rate for a cohort is defined as [31]
I≡incidence rate incohort ¼ totalnumberof cases in the timeperiod
totalpersonyearsat riskduring the timeperiod
:
Let P be the cohort population, ni the number of new
cases in year i, and Y the number of years in the study
period. The total number of cases (N) during the study
period is given by
N ¼
XY
i¼1
ni
and the incidence rate can be expressed as
I ¼ N
Y  ðP−NÞ þP
i¼1
Y ði−0:5Þ  ni
:
Data on cases of cancer in the general population was
acquired from publicly available cancer registration data
(available from The Office for National Statistics web-
site). Specifically, we used registrations of newly diag-
nosed cases of cancer in England between 1995 and
2014 inclusive as this was the most comprehensive data.
Therefore, we used a 20-year study period from 1995 to
2014 as the primary analysis and so the incidence rate
can be written as
I ¼ N
20 ðP−NÞ þP
i¼1995
2014
ði−1995þ 0:5Þ  ni
:
The figure used for the population of England was the
2005 mid-year estimate taken from The Office of Na-
tional Statistics data (50,606,000 individuals).
The cancer incidence rate for the Fabry cohort and
general population cohort were compared as an inci-
dence rate ratio [31]
IR ¼ incidence rate ratio ¼ IFabry
IGen pop
:
The standard deviation of log(IR) was calculated using
SD In IRð Þ½  ¼ 1
NFabry
þ 1
NGen pop
0:5 
and the lower and upper limits of the rate ratio calcu-
lated using
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IR:IR ¼ expfIn IRð Þ  1:96SD In IRð Þ½ ⋅
The method above excludes cancer cases pre-1995 and
post-2014. In the Fabry cohort there were 2 cancer diag-
noses pre-1995 and 5 cancer diagnoses post-2014. We
therefore decided to also perform the calculations using
a 22-year study period from 1995 to 2016. To do this we
estimated cancer incidence in the general population in
2015 and 2016 as the same as in 2014.
Administrative requirements
Ethics approval was gained from University College
London (UCL) and the Integrated Research Application
System (IRAS). Patient information was kept confiden-
tial and managed in accordance with trust data protec-
tion guidance (which incorporates the Data Protection
Act of 1998).
Results
Characteristics of the study population
The case notes and/or questionnaire data of 261 adult
patients who attended the Royal Free Hospital
Lysosomal Storage Disorder unit between 2012 and
2016 were included in the data analysis. Of these 163
(62%) were female and 98 (38%) were male. The median
age was 53 years, with a lower quartile age of 41 years
and an upper quartile age of 64 years. The majority of
patients were Caucasian. Eighty four male patients (86%)
and 80 female patients (49%) were receiving enzyme re-
placement therapy (ERT). All patients had a confirmed
genetic diagnosis of Fabry disease.
Characteristics of the general UK population
As we will go on to compare the Fabry population to the
general population, it is worth briefly describing some
features of the UK population which have relevance to
cancer incidence. Whilst almost all of the Fabry patients
are Caucasian the UK population is more diverse, with
86% of the population identifying with a White ethnic
group in the 2011 Census (Office for National Statistics).
The median age of the UK population in 2014 was
40 years, with a lower quartile age of 21 years and an
upper quartile age of 58 years (Office for National
Statistics).
Characteristics of patients identified with cancer
Twenty-five patients (10%) had a previous or current
diagnosis of cancer (Table 1). This was comprised of 17
females and 8 males. The most common cancer in fe-
males was breast cancer (7 cases) and in males was renal
cell carcinoma (2 cases). Four patients were diagnosed
with melanoma and 5 patients were diagnosed with uro-
logical malignancies (1 female with bladder cancer, 1
male with ureteric cancer, 1 female with renal cancer
and 2 males with renal cancer). One female and 1 male
were diagnosed with 2 separate malignancies; patient 9
had breast cancer and melanoma and patient 25 had
renal cell carcinoma (clear cell) and prostate
adenocarcinoma.
Comparison with general population cancer incidence
rates
Using publicly available data from The Office for Na-
tional Statistics the all-cancer (excluding non-melanoma
skin cancer) incidence rate for the general population
(using the study period 1995 to 2014) was 519 new cases
per 100,000 per year. To calculate an all-cancer (exclud-
ing non-melanoma skin cancer) incidence rate for the
Fabry population that was comparable to the above we
had to exclude 7 individuals from the 25 with a current/
past diagnosis of cancer. This included 2 patients with
basal cell carcinoma (patients 11 and 20), 2 patients who
had been diagnosed before 1994 (patients 9 and 19) and
5 patients who had been diagnosed after 2014 (patients
1, 13, 18 and 23 and 24). The all-cancer (excluding non-
melanoma skin cancer) incidence rate of the Fabry
population was 316 per 100,000 per year. The incidence
rate ratio of the Fabry population compared to the gen-
eral population was 0.61 (95% confidence interval 0.37
to 0.99).
The above approach has the disadvantage of excluding
7 of the 25 individuals with cancer. Therefore, we also
compared cancer in the Fabry population and general
population over longer study period, namely 1994 to
2016. To do this we made the assumption that cancer
incidence in the general population in both 2015 and
2016 was the same as in 2014. This meant only 4 pa-
tients were excluded from the analysis. The cancer inci-
dence rate for the general population became 531 per
100,000 per year and the cancer incidence rate in the
Fabry population was 379 per 100,000 per year. The in-
cidence rate ratio of the Fabry population compared to
the general population was 0.71 (95% confidence interval
0.46 to 1.1).
As there were 5 cases of urological cancer and 4 cases
of melanoma we compared the incidence rate of these
specific cancers in the Fabry and general population.
The incidence rate of malignant neoplasm of kidney,
renal pelvis, ureter, bladder, other and unspecified urin-
ary organs in the general population was 32 per 100,000
per year (for both the 20-year and 22-year study period).
Of the 5 cases in the Fabry cohort, 2 were excluded from
the 20-year analysis as they were diagnosed after 2014
(patients 18 and 23). The incidence rate of malignant
neoplasm of kidney, renal pelvis, ureter, bladder, other
and unspecified urinary organs in the Fabry population
was 58 per 100,000 per year (1995 to 2014) and the inci-
dence rate ratio of the Fabry population compared to
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the general population was 1.8 (95% confidence interval
0.58 to 5.6). With the 22-year study period, the inci-
dence rate in the Fabry cohort was 88 per 100,000 per
year and the incidence rate of the Fabry population com-
pared to the general population was 2.7 (95% confidence
interval 1.1 to 6.5). Given the significant effects of Fabry
disease on the kidney parenchyma we also repeated the
analysis for incidence rate of malignant neoplasm of the
kidney, except renal pelvis. There were 3 cases of renal
carcinoma in the Fabry cohort; 2 were included in the
20-year study period (as patient 18 was diagnosed in
2015) and all 3 were included in the 22-year study
period. The incidence rate of malignant neoplasm of the
kidney (except pelvis) in the general population was 12
per 100,000 per year (for both the 20-year and 22-year
study periods). The incidence rate in the Fabry popula-
tion was 38 per 100,000 per year for the 20-year study
period, giving an incidence rate ratio of the Fabry
population compared to the general population of 3.3
(95% confidence interval 0.83 to 13). In the 22-year
study period, the incidence rate in the Fabry population
was 52 per 100,000 per year, giving an incidence rate ra-
tio of the Fabry population compared to the general
population of 4.3 (95% confidence interval 1.4 to 13).
The malignant melanoma incidence rate in the general
population is 16 per 100,000 per year (study period 1995
to 2014). One of the 4 melanoma cases in the Fabry co-
hort was excluded from the analysis as she had been di-
agnosed in 1987 (patient 9). The incidence rate of
malignant melanoma in the Fabry population was 58 per
100,000 per year (study period 1995 to 2014). The inci-
dence rate ratio of the Fabry population compared to
the general population was 3.6 (95% confidence interval
1.2 to 11). In the Fabry cohort there were no melanoma
diagnoses post 2014. When the calculations were re-
peated with the extended study period (1994 to 2016),
Table 1 Cancer cases in the Fabry cohort
Patient
number
Gender Year of
birth
Year of cancer
diagnosis
Cancer Type Status ERT Smoking Family history of
cancer (type)
1 Female 1982 2016 Colon Alive No Unknown Father (unknown)
2 Female 1963 1999 Melanoma Alive Yes No Mother (bowel)
3 Female 1962 2007 Bowel Alive Yes No No
4 Female 1961 2000 Melanoma Alive No No No
5 Female 1960 2004 Breast Alive Yes No Unknown
6 Female 1953 2014 Breast Alive Yes Yes Unknown
7 Female 1952 2008 Breast Alive Yes Yes No
8 Female 1952 2005 Breast Alive No No Paternal grandmother
(unknown)
9 Female 1947 1987 and 2006 Melanoma, breast Alive No Unknown No
10 Female 1945 2004 Breast Alive No No No
11 Female 1939 Unknown Basal cell Alive Yes No No
12 Female 1936 2001 Breast Alive No No No
13 Female 1935 2016 Lung Alive Yes Yes No
14 Female 1934 1998 Lymphoma Alive No No Mother (renal)
15 Female 1932 1999 Colon Alive No No No
16 Female 1927 2006 Bladder Lost to
follow-up
No No Mother (liver)
17 Female Unknown 2000 Renal Unknown Unknown Unknown Unknown
18 Male 1982 2015 Renal Deceased No Unknown Unknown
19 Male 1956 1981 Testicular Alive Yes No Father (eyelid)
20 Male 1953 2010 Basal cell Alive Yes No No
21 Male 1947 2002 Melanoma Alive Yes Yes No
22 Male 1944 2010 Mesothelioma Deceased Yes No No
23 Male 1940 2016 Left ureteric transitional
cell
Alive Unknown Unknown Unknown
24 Male 1940 2016 Chronic lymphocytic
leukaemia
Alive No Ex-smoker No
25 Male 1930 2008 Renal cell and prostate Alive Yes No No
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the incidence rate in the general population was 17 per
100,000 per year, the incidence rate in the Fabry cohort
was 53 per 100,000 per year and the incidence rate ratio
was 3.1 (95% confidence interval 0.99 to 9.5).
Characteristics of patients identified with benign lesions
Twenty-four patients in the cohort (9%), 17 females and
7 males, had one or more diagnoses of benign lesions
(Table 2). The most common were growths in neuro-
logical tissues (5 cases), colon polyps (5 cases), benign
breast lesions (4 cases), atypical moles (3 cases), renal le-
sions (2 cases) and cervical intraepithelial neoplasm (2
cases).
Three patients were diagnosed with two benign lesions;
patient 34 had fibroadenoma of the breast and lipoma,
patient 38 had colon polyps and renal nodule and patient
43 had neurofibroma and haemangioma.
Five patients were diagnosed with both a cancer
and a benign lesion; patient 1 had atypical mole and
colon cancer, patient 4 had atypical mole and melan-
oma, patient 13 had colon polyp and lung cancer, pa-
tient 16 had benign breast neoplasm and bladder
carcinoma, and patient 20 had left ear cholesteatoma
followed by basal cell carcinoma.
Comparison with general population meningioma
incidence rates
Benign tumours and precancerous lesions in the general
population are not systematically recorded in the man-
ner of malignancies and therefore it was not possible to
Table 2 Cases of benign lesions in the Fabry cohort
Patient
number
Gender Year of
birth
Year of benign
lesion diagnosis
Benign lesion Status ERT Smoking Family history of
cancer (type)
26 Female 1986 Unknown Benign acoustic neuroma Alive No No Unknown
27 Female 1984 2004 Cervical intraepithelial neoplasia Alive Yes No Maternal
grandmother
(unknown)
1 Female 1982 Unknown Atypical mole Alive No Unknown
28 Female 1979 2011 Small falx meningioma Lost to
follow-up
No No Father (unknown)
29 Female 1976 Unknown Cervical intraepithelial neoplasia Alive No Unknown No
30 Female 1975 2005 Fibroadenoma of breast Alive No Yes No
31 Female 1972 2007 Atypical mole Alive No No No
32 Female 1969 1987 Craniopharyngioma Alive No No No
33 Female 1966 2010 Prolactinoma Alive No Yes Unknown
34 Female 1962 2001 and 2003 Fibroadenoma of breast,
lipoma
Alive Yes Yes No
4 Female 1961 2001 Atypical mole Alive No No No
35 Female 1961 2009 Breast benign lesion Alive Yes No Unknown
36 Female 1959 Unknown Colon polyp Lost to
follow-up
Yes Yes No
37 Female 1958 2016 Meningioma Alive Yes Unknown Unknown
38 Female 1943 1990, 1995 and
2011
Colon polyps ×2, nodular
lesion left adrenal
Alive Yes Ex-smoker No
13 Female 1935 2001 Colon polyp Alive Yes Ex-smoker No
16 Female 1927 1972 Benign breast neoplasm Lost to
follow-up
No No Mother (Liver)
20 Male 1953 1974 Left ear cholesteatoma Alive Yes No No
39 Male 1951 2006 Gastric dysplasia Lost to
follow-up
Yes No Unknown
40 Male 1949 2005 Colon polyp Alive Yes Yes Unknown
41 Male 1939 2010 Adrenal adenoma Alive Yes Ex-smoker No
42 Male 1935 2010 Monoclonnal gammopathy of
undetermined significance (MGUS)
Lost to
follow-up
Yes No No
43 Male 1933 2009 Neurofibroma, haemangioma Deceased Yes Ex-smoker No
44 Male 1931 2001 and 2006 Colonic polyps Deceased Yes Ex-smoker No
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compare our Fabry cohort to the general population ex-
cept in the case of benign neoplasm of meninges.
There were 2 diagnoses of benign neoplasm of the men-
inges in the Fabry cohort. For the 20-year study period
(1995 to 2004) the incidence rate of benign neoplasm of
meninges in the general population was 2.8 per 100,000
per year. One diagnosis of benign meningioma occurred
between 1995 and 2014 and the incidence rate of benign
neoplasm of meninges in the Fabry population over this
period was 19 per 100,000 per year. The incidence rate ra-
tio of the Fabry population compared to the general popu-
lation was 6.8 (95% confidence interval 0.96 to 49).
For the 22-year study period (1995 to 2016) the incidence
in the general population was 2.9 per 100,000 per year and
the Fabry population was 35 per 100,000 per year. The inci-
dence rate ratio was 12 (95% confidence interval 3.0 to 48).
Discussion
Cancer in patients with Fabry disease
All cancer (excluding non-melanoma skin cancer) incidence
Our study identified 25 cases of cancer in the Fabry co-
hort. When compared to the general population there ap-
peared to be a borderline-significant reduction in risk of
cancer in the Fabry patients with an incidence rate ratio of
0.61 (95% confidence interval 0.37 to 0.99) in the 1995–
2014 analysis and an incidence rate ratio of 0.71 (95% con-
fidence interval 0.46 to 1.1) in the 1995–2016 analysis.
Reliable comparison of our small Fabry patient cohort to
the general population is challenging due to multiple con-
founding factors which may explain the difference in cancer
risk. The demographics of the two populations also differ
with a median age of around 41 years in the general popula-
tion and 53 years in the Fabry population. The Fabry popu-
lation is followed up yearly in clinic and frequent interaction
with health care services may lead to a healthier lifestyle
and earlier risk factor intervention. For example, Fabry pa-
tients have their smoking status, weight, blood pressure,
cholesterol and basic bloods monitored at each clinic visit.
In addition, frequent medical reviews may help to identify
precancerous lesions before they become malignant.
There may also be ascertainment bias and cases of can-
cer in the cohort may be missing. In this study, a high
proportion of the cancer cases were recent diagnoses, sug-
gesting recording of malignancies could have improved
and older cases may be missing from the dataset. Simi-
larly, a study of malignancy in Gaucher disease described
a lower risk of solid tumours (when compared to the gen-
eral population) and ascertainment bias was recognised as
a potential factor [25].
However, it is possible that alteration in the sphingo-
lipid profile could impact on cancer development. Fabry
disease affects endothelial cells and results in abnormal
tissue perfusion; since angiogenesis is a requirement for
tumour growth, neoplasia in Fabry disease may be
compromised by chronic ischemia [32]. In addition, a
higher baseline apoptotic rate may be protective against
malignant transformation [33].
Urological cancers
There were 5 cases of urological cancer in the Fabry co-
hort. Two were excluded in the 20-year analysis and
there was an incidence rate ratio of 1.8 (95% confidence
interval 0.58 to 5.6). However, in the 22-year analysis all
5 cases could be included and this led to an incidence
rate ratio of 2.7 (95% confidence interval 1.1 to 6.5).
Considering renal cancer alone, there were 2 cases in
the 20-year analysis with an incidence rate ratio of 3.3
(95% confidence interval 0.83 to 13) and 3 cases in the
22-year analysis with an incidence rate ratio of 4.3 (95%
confidence interval 1.4 to 13). Therefore, this may repre-
sent an excess of urological malignancy, and also specif-
ically renal cancers, in the Fabry cohort.
This is of particular relevance because the kidneys can be
severely affected in Fabry disease, with proteinuria and end
stage renal function possible if the condition is untreated
[6]. Chronic kidney damage and inflammation may be car-
cinogenic, as could exposure to excess sphingolipids.
Patients with Fabry disease have more frequent investi-
gation compared to the general population, including
blood tests, urine analysis and renal ultrasounds. This
might lead to an increase in the detection of renal carcin-
oma, however the natural history of renal cancer would
suggest that similar cases in the general population would
not go undetected indefinitely [34].
There is one case of testicular cancer in the Fabry co-
hort. This is of particular interest because azoospermia
and infertility are common in ‘classic’ Fabry males and,
should more cases of testicular cancer emerge, the mecha-
nisms behind the defects in testicular function may merit
further investigation [35].
Malignant melanoma
We also detected a possible excess of melanoma in the
Fabry cohort, with an incidence rate ratio of 3.6 (95%
confidence interval 1.2 to 11) in the 20-year analysis and
an incidence rate ratio of 3.1 (95% confidence interval
0.99 to 9.5) in the 22-year period.
Skin changes, such as angiokeratoma and telangiecta-
sia, are common manifestations of Fabry disease and the
presence of cutaneous vascular lesions is correlated with
the severity of systemic manifestations [36]. It is possible
that abnormalities in the skin could be linked to the in-
creased rates of melanoma in Fabry patients.
However, the majority of patients in the Fabry cohort
are Caucasian (which confers a higher risk of melanoma)
and the national data is likely to reflect the greater vari-
ation of ethnicities and skin types in the general popula-
tion. We were also unable to collect further data regarding
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risk factors such as sun exposure. Skin is reviewed fre-
quently in clinic and many patients will have formal
dermatology check-ups. Higher detection rates may ex-
plain this apparent excess but, as with urological cancer,
malignant melanoma inevitably tends to self-declare.
Benign lesions in patients with Fabry disease
Twenty-four patients in the Fabry cohort had a docu-
mented benign lesion. Whilst benign breast lesions, colon
polyps and atypical moles are frequently seen in clinical
practice, benign growths of neurological tissues were the
most common benign lesion in Fabry patients (5 cases).
There is a single case report of 3 Fabry patients with men-
ingiomas [37].
Benign growths of neurological tissue may be over
represented in our series; given the high stroke risk in
Fabry, these patients have routine brain MRI scans and
thus some meningiomas could be incidental findings.
However, it is possible that vascular abnormalities in
Fabry disease contribute to benign brain tumour growth.
Conclusion
Overall our data suggests that patients with Fabry
disease do not seem to be at highly increased risk of
cancer development. However, there may be an in-
creased incidence of melanoma, urological cancers
and benign meningioma in Fabry patients. This could
be due stimulation by lyso-lipids, disease-related in-
flammation and vascular abnormalities. Limitations of
our study include recall bias and ascertainment bias
(due to increased monitoring frequency of the popu-
lation). Further studies should address these problems
prospectively, in a larger cohort of patients.
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